NCT03384238View on ClinicalTrials.gov

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2027

Conditions
Pancreatic Adenocarcinoma
Interventions
PROCEDURE

Fluorescence Imaging

Undergo fluorescence imaging

BIOLOGICAL

Panitumumab

Given IV

DRUG

Panitumumab-IRDye800

Given IV

Trial Locations (1)

94304

RECRUITING

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eben Rosenthal

OTHER